Lenz Therapeutics Reports 110,000 VIZZ Prescriptions Since Launch
Bitget2026/10/28 23:18- Lenz Therapeutics reported 50% quarter-over-quarter growth in Q3 2026, with VIZZ reaching 110,000 total prescriptions since launch.
- Cash totaled approximately $197 million as of Q3 2026.
- Eleven international regulatory applications are under review, with the first approval anticipated as early as Q4 2026.
- Up to five international regulatory approvals are expected by the end of 2027.
- VIZZ has eight granted US patents extending up to 2044, with US new chemical entity regulatory exclusivity through 2030.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
